Clinical significance
(1) In type 2 diabetes mellitus, APMCG-1, a PI3K/AKT activator, protects
against oxidant-induced dysfunctions in skeletal myoblasts and
cardiomyocytes.
(2) This finding provides fresh light on the potential of glycopeptides
as a treatment for muscle-related conditions.